Xvivo Perfusion ABXVIPF -1.32%91 EBIT per Share is $0.32 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 99.28% on this metric.
Xvivo Perfusion AB's EBIT per Share for the
three
months ended in Mar. 2026 was $0.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.32.
During the past 12 months, the average EBIT per Share Growth Rate of Xvivo Perfusion AB was -2.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 168.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Xvivo Perfusion AB's EBIT per Share or its related term are showing as below:
XVIPF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -34.7 Med: 0.6 Max: 168.4
Current: 168.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Xvivo Perfusion AB was 168.40% per year. The lowest was -34.70% per year. And the median was 0.60% per year.
XVIPF's 3-Year EBIT Growth Rate is ranked better than 99.28% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.65
vs XVIPF: 168.40
Xvivo Perfusion AB (OTCPK:XVIPF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Xvivo Perfusion AB EBIT per Share Related Terms
Xvivo Perfusion AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a EBIT per Share of $0.32 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #5 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 0.7%.
Is Xvivo Perfusion AB's EBIT per Share too high?
Xvivo Perfusion AB's current EBIT per Share is $0.32. The Medical Devices & Instruments industry median EBIT per Share is 9.65. Xvivo Perfusion AB's value of $0.32 is 96.7% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #5 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #5 out of 690 companies for EBIT per Share. This places Xvivo Perfusion AB in the top 1% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.65. Xvivo Perfusion AB's value of $0.32 is 96.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current EBIT per Share of $0.32 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current EBIT per Share is $0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current EBIT per Share is $0.32 and 96.7% below the Medical Devices & Instruments industry median of 9.65. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current EBIT per Share is $0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
EBIT per Share: $0.32
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 96.7% below the Medical Devices & Instruments median (#5 of 690)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
